The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial of regorafenib, hydroxychloroquine, and entinostat in metastatic colorectal cancer.
 
Timothy J Brown
No Relationships to Disclose
 
Thomas Benjamin Karasic
Honoraria - Exelixis; Incyte; Pfizer
Research Funding - Bristol-Myers Squibb; Celgene; H3 Biomedicine; Lilly; Sirtex Medical; Syndax; Taiho Pharmaceutical; Tempest Therapeutics
 
Charles John Schneider
No Relationships to Disclose
 
Ursina R. Teitelbaum
No Relationships to Disclose
 
Kim Anna Reiss
Honoraria - MJH Life Sciences
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology; Lilly (Inst); Tesaro (Inst)
 
Tara C. Mitchell
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; OncoSec
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); Roche (Inst)
Travel, Accommodations, Expenses - BMS; Merck
 
Ryan Campbell Massa
No Relationships to Disclose
 
Mark H. O'Hara
Consulting or Advisory Role - Geneos; Natera
Research Funding - Arcus Biosciences; Bristol-Myers Squibb; Celldex; Lilly; Natera; Parker Institute for Cancer Immunotherapy
Travel, Accommodations, Expenses - AstraZeneca/MedImmune
 
Lisa DiCicco
No Relationships to Disclose
 
Luis Garcia-Marcano
No Relationships to Disclose
 
Ravi K. Amaravadi
No Relationships to Disclose
 
Peter J. O'Dwyer
Consulting or Advisory Role - Array BioPharma; Genentech
Research Funding - Amgen (Inst); Array BioPharma (Inst); BBI Healthcare (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Lilly/ImClone (Inst); Minneamrita Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Syndax (Inst); Syndax (Inst); syndax (Inst); Syndax (Inst); Syndax (Inst); Taiho Pharmaceutical (Inst)
Expert Testimony - Lilly